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Summary
Fas ligand (FasL) is a type II integral membrane protein homologous with tumor necrosis factor
(TNF) . Recent studies indicate that TNF is processed to yield the soluble cytokine by metallo-
proteinases at the cell surface of activated macrophages and T cells. In the present study, we in-
vestigated whether FasL is also released by metalloproteinases. Treatment with hydroxamic acid
inhibitors of matrix metalloproteinases specifically led to accumulation ofmembrane-type FasL
(p40) on the surface of human FasL cDNA transfectants and activated human T cells, as esti-
mated by surface immunofluorescence and immunoprecipitation with newly established anti-
human FasL monoclonal antibodies. This surface accumulation of mFasL was associated with
the decrease of soluble FasL (p27) in the supernatant as estimated by quantitative ELISA and
immunoprecipitation with anti-human FasL monoclonal antibodies. These results indicate that
human FasL is efficiently released from the cell surface by metalloproteinases like TNF.
F
as (APO-1, CD95) is a type I integral membrane pro-
tein initially identified by mAbs that induce apoptotic
cell death upon binding to certain tumor cells (1, 2) . Mo-
lecular cloning of Fas revealed that it belongs to the TNF
receptor family and transducer a cell death signal (3). Fas is
expressed on activated lymphocytes and in various tissues,
including the liver, lung, intestine, and skin (4, 5). It has
been reported that administration of an agonistic anti-Fas
mAb rapidly killed mice by severely damaging the liver (6) .
Recent molecular cloning of Fas ligand (FasL)l revealed
that it is a type II integral membrane protein homologous
with TNF (7). FasL is expressed on activated T and NK
cells, and mediates Fas+ target cell lysis by these effector
cells (8-10). The Fas/FasL system also been also implicated
in the pathogenesis of autoimmune diseases, fulminant
hepatitis, GVHD, and AIDS (11-13) .
TNF-a, a prototype cytokine of the TNF family, has
been well known to be released as the 17-kD secretory
form from the 26-kD membrane form (14) . Recent studies
indicated that this processing is performed by some matrix
metalloproteinases (MMPs) (15-17) . It has also been re-
cently reported that human FasL was released as a 26-kD
soluble form from COS cells transfected with human FasL
cDNA and activated human T cells (18) . In this context,
we demonstrate here that human FasL is also released by
'Abbreviations used in this paper: c1G, control Ig; FasL, Fas ligand; rnFasL,
membrane FasL; FFasL, soluble FasL; MMP, matrix metalloproteinase;
P+l, PMA plus ionomycin; RT, reverse transcription.
MMPs such as TNF-ot, as estimated by specific blocking by
MMP inhibitors. Physiological and clinical relevance ofthis
finding is discussed.
Materials and Methods
Cells.
￿
Mouse T lymphoma cell lines (L5178Y and WR19L)
and human Fas cDNA transfectant (hFas/WR19L) (3) were
kindly provided by Dr. S. Yonehara (Kyoto University, Kyoto,
Japan) and cultured in RPMI-1640 medium containing 10%
FCS, 100 N,g/ml each streptomycin and penicillin, and 2 mM
glutamine (culture medium) . A human CD4+ T cell clone
(4HM1) of Thl type was provided by Dr. M . Azuma (Juntendo
University, Tokyo) and maintained in the culture medium sup-
plemented with 50 U/ml ofrIL-2.
Reagents.
￿
The following hydroxamic acid-based metallopro-
teinase inhibitors were synthesized by Kanebo Ltd. (Osaka, Japan):
[4-(N-hydroxyamino)-2R-isobutyl-3S-(2-thienylthiomethyl)succi-
nyl]-L-phenylalanine-N-methylamide (131394) (19), [4-(N-hy-
droxyamino)-2R-isobutyl-3S-methylsuccinyl]-L-3-(5,6,7,8-tetra-
hydro-l-naphthyl)alanine-N-methylamide (KB8301), and [4-(N-
hydroxyamino)-2R-phenylpropylsuccinyl]-L-3-cyclohexylalanine-
N-[2-(4-sulphonamidophenyl)ethyl]amide (KB8112) (20). A non-
hydroxamate derivative of KB8301, (4-hydroxy-2R-isobutyl-3S-
methylsuccinyl)-L-3-(5,6,7,8-tetrahydro-1-naphthyl)alanine-N-
methylamide (KB8845), was also synthesized as a negative control.
These compounds are available upon request. Other protease in-
hibitors, including aprotinin, leupeptin, pepstatin, E64, Bestatin,
captopril, and phosphoramidon, were purchased from Sigma
Chemical Co. (St. Louis, MO) . All these protease inhibitors were
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mycin were also purchased from Sigma. OKT-3 mAb was pre-
pared from the hybridoma obtained from the American Type
Culture Collection (Rockville, MD). An anti-Fas mAb (clone
CH-11) was purchased from MBL (Nagoya, Japan) . Preparation
of the soluble Fas-Ig fusion protein has been described previ-
ously (8).
Generation ofHuman FasL Transfectants.
￿
Human Fast cDNA was
prepared by reverse transcription (RT)-PCR from total RNA of
activated 4HM1 by using an oligonucleotide corresponding to
the first six codons as the 5' primer and to the last six codons as
the 3' primer, according to the published sequence (21). The 5'
and 3' primers were tagged with a Xhol or a Nod site, respec-
tively. After XhoI and Nod digestion, the PCR product of 850
by was subcloned into pBluescriptIl SK+ (Stratagene, La Jolla,
CA) and the nucleotide sequence was confirmed by sequencing.
The 850-bp cDNA was then transferred into the Xhol and Nod
sites ofthe CDM8 or BCMGSneo expression vector (22), kindly
provided by B. Seed (Massachusetts General Hospital, Boston,
MA) and H. Karasuyama (Tokyo Metropolitan Institute of Med-
ical Science, Tokyo), respectively. Transient expression ofhuman
FasL cDNA (hFasL/CDM8) in COS cells was performed as de-
scribed previously (8) . Culture supernatant containing soluble
FasL (sFasL) was collected after 4 d. For generating stable trans-
fectants, hFasL/BCMGSneo was transferred into L5178Y cells by
electroporation (290V; 960p,F), using a gene pulser (Bio-Rad,
Hercules, CA) . After selection with 0.4 mg/ml G418 and cloning
by limiting dilution, a transfectant (hFasL/L5178Y) expressing a
high level of hFasL mRNA was selected by Northern hybridi-
zation.
Generation ofAnti-human FasL MAbs.
￿
4-wk old female MRL
1pr/ 1pr mice (ClearJapan, Tokyo) were immunized by intraperi-
toneal injection ofhFasL/L5178Y (10' cells) several times at 10-d
intervals. 3 d after final immunization, the splenocytes were fused
with P3U1 mouse myeloma cells, as described previously (23).
After HAT selection, the antibodies that neutralize Cytotoxic ac-
tivity of sFasL in the hFasL/L5178Y supernatant against hFas/
WR19L were screened. Three mAbs (NOK-1, NOK-2, and
NOK-3) were identified by their strong inhibitory effects and
cloned by limiting dilution. NOK-1 (mouse IgG1,ic) and NOK-2
(mouse IgG2a,ic) were purified from ascites by protein G affinity
chromatography. NOK-3 (mouse IgM,ic) was purified by ammo-
nium sulfate precipitation and gel filtration.
Cytotoxic Assay.
￿
Cytotoxic activity ofsFasL in the culture su-
pernatants was tested against the human Fas transfectant by the
alamar Blue method, according to the manufacturer's instructions
(Alamar Biosciences, Inc., Sacramento, CA). Briefly, hFas/
WR19L or WR19L cells (104) were cultured with serially diluted
hFasL/COS or hFasL/L5178Y supernatant in a total volume of
100 l.tl. After 16 h, 10 p.,l of alamar Blue was added and further
incubated for 4 h. Fluorescence of the reduced alamar Blue was
measured on a Fuoroskan (Titertek Fluoroskan II; Labosystems
Japan, Tokyo) at 590 nm by excitation at 544 nm.
Immunofluorescence.
￿
L5178Y or hFasL/L5178Y cells (106/ml)
were cultured with or without various protease inhibitors (10
N,M, unless otherwise indicated) for 24-48 h. 4HM1 cells (106/
ml) were stimulated with ionomycin (500 ng/ml) and PMA (10
ng/ml) in the presence or absence of 10 p,M BB94 for 2-6 h.
These cells (106) were incubated with 1 jig ofbiotinylated NOK-1
for 1 h at 4°C, followed by PE-labeled avidin (PharMingen, San
Diego, CA) . After washing with PBS, the cells were analyzed on
a FACScan (Becton Dickinson & Co., San Jose, CA), and data
were processed by using the CELLQuest program.
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ELISAfor sFasL, TNF-a, and IFN-y.
￿
hFasL/L5178Y cells (106/
ml) were cultured with or without various protease inhibitors for
24 h. sFasL in the supernatant was quantitated by sandwich
ELISA using NOK-1 and NOK-3. Briefly, Immulon 2 plates
(Dynatech Laboratories Inc ., Chantilly, VA) were incubated
overnight with NOK-3 (10 jig/ml). After washing with 0.05%
Tween/PBS, the wells were blocked by skimmed milk solution
(Block Ace; Snow Brand Milk Co., Sapporo, Japan) for 2 h at
37°C, 50 N.1 of the sample were added and incubated for 1 h at
room temperature, biotinylated NOK-1 (5 jig/ml) was added
and incubated for 1 h at room temperature, and 50 wl ofABC so-
lution (Vectastain ABC kit; Vector Laboratories Inc., Burlin-
game, CA) was added and incubated for 30 min at room temper-
ature. The plates were developed with 100 ~d of I mg/ml
orthophenylenediamine in 50 mM citrate-phosphate buffer (pH
5.0) containing 0.03% H,O,, and stopped with 100 [,1 of 2N
H2SO4- OD at 490 nm was measured on an automated ELISA
reader. Serial dilutions ofpurified sFasL, which was affinity puri-
fied from the hFasL/L5178Y supernatant on a NOK-1 column,
was used as the standard. Detection limit of this assay was -0.2
ng/ml. 4HM1 cells (106/ml) were stimulated with immobilized
OKT-3 (10 N,g/ml) in the presence or absence ofvarious protease
inhibitors for 24 h. sFasL in the supernatant was measured as de-
scribed above. TNF-a and IFN-'Y in the supernatants were eval-
uated with commercial ELISA (R & D Systems, Minneapolis,
MN) according to the manufacturer's instruction .
Immunoprecipitation .
￿
To identify the cellular FasL, hFasL/L5178Y
cells (106/nil) were cultured with 100 1LCi/ml Of [35S]Cys/Met
(TransLabel; ICN Biomedical Inc., Costa Mesa, CA) in the pres-
ence of 10 1LM BB94 at 37°C for 16 h. After chasing in fresh cul-
ture medium with 10 RM BB94 at 37°C for 4 h, the cells were
extracted with a lysis buffer (0.5% Triton X-100, 20 mM Tris-
HCI, pH 7.6, 150 mM NaCl, 10 ILM PMSF, and 50 N,g/ml
trypsin inhibitor). To identify the sFasL, hFasL/L5178Y cells
were cultured with 100 lLCi/ml of [35S]Cys/Met in the absence
of BB94 at 37°C for 24 h, and the supernatant was collected. Af-
ter preclearing with normal mouse control Ig (clg)-coupled Seph-
arose, the lysate and supernatant were immunoprecipitated with
NOK-1-coupled Sepharose for 1 h at 4°C . After washing with
the lysis buffer, the bound materials were eluted and subjected to
SDS-PAGE under nonreducing or reducing (5% 2-ME) condi-
tions. For fluorography, gels were incubated with Amplify (Am-
ershamJapan, Tokyo) for 30 min, dried, and exposed to x-ray film
(XAR-5; Eastman Kodak, Rochester, NY) at -80°C for 1 d.
For pulse-chase analysis, 4HM1 cells (106/ml) were labeled
with 100 p,Ci/ml of [35S]Cys/Met in the presence of ionomycin
plus PMA at 37°C for 1 h, then chased in the culture medium
with or without 10 N,M BB94 for 1-6 h. Supernatants and cell ly-
sates were prepared from the same culture and immunoprecipi-
tated with NOK-1-Sepharose. The eluates were subjected to
SDS-PAGE and fluorography as described above. Intensities of
the p40 and p27 bands were measured on an image analyzer
(Fujix BAS 2000; Fuji Photo Film Co. Ltd., Tokyo).
To identify the membrane Fast (mFasL), hFasL/L5178Y cells
were surface-labeled with sulfo-N-hydroxysuccinimide-biotin, as
described previously (23). The cells were extracted with the lysis
buffer, precleared with clg-Sepharose, and immunoprecipitated
with NOK-1-Sepharose. After washing with the lysis buffer, the
eluates were subjected to SDS-PAGE and electroblotted onto ni-
trocellulose membrane filters. The blots were subsequently incu-
bated with Vectastain ABC solution, developed with ECL West-
ern blotting detection reagents (AmershamJapan), and exposed to
x-ray films for a few minutes.Results and Discussion
Human Fast, cDNA Transfectants Release Functional Fast,.
To characterize the functional properties of human Fast,,
we generated a stable transfectant. Human Fast, cDNA was
prepared by RT-PCR from totalRNA of activated human
T cell clone (4HM1) and introduced into a mouse T lym-
phoma cell line (L5178Y) that does not express Fas (8) . A
clone (hFasL/L5178Y) expressing a high level ofFast, mRNA
was selected. This cell line exhibited a high spontaneous
cytotoxic activity against hFas/WR19L but not against
WR19L in a 4-h "Cr release assay (data not shown), indi-
cating the expression of functional Fast,. Recently, Tanaka
et al. reported the presence of a functional soluble form of
human Fast, (hereafter termed sFasL) in the culture super-
natant of human Fast, cDNA-transfected COS cells (18). We
also observed that the culture supernatant of hFasL/L5178Y
as well as that of human Fast, cDNA-transfected COS cells
A
B
Dilution of Supernatant(fold)
Figure 1.
￿
Release of functional sFasL from hFasL/L5178Y. Cytotoxic
activity of sFasL in the supernatant of hFasL/L5178Y (9,O) or hFasL/
COS (",L) and that of an anti-Fas mAb (",D) was tested against hFas/
WR19L (",",") or WR19L (O,A,D) cells by the Alamar blue method.
Data represent mean ± SD of triplicate samples. In B, sFasL concentra-
tion in the supernatants was determined by ELISA, and the abscissa is nor-
malized as the concentration ofsFasL and anti-Fas mAb.
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exhibited specific cytotoxicity against hFas/WR19L in a
dose-dependent manner (Fig. 1 A). As measured by the
sandwich ELISA described below, the hFasL/L5178Y and
hFasL/COS supernatants contained sFasL at 13.5 ng/ml
and 8.7 ng/ml, respectively. When dilution ofthe superna-
tant was converted to the concentration of sFasL (Fig. 1 B),
sFasL derived from the L5178Y and COS transfectants ex-
hibited almost comparable specific activity (ED50 = 3.4 ng/
ml and 2 .9 ng/ml, respectively). These were also compara-
ble to the specific activity of natural sFasL derived from
anti-CD3-stimulated 4HM1 (data not shown) . In compar-
ison, the most widely used agonistic anti-Fas mAb (CH-11)
exhibited 2.5-fold lower specific activity (EDso = 8.1 ng/
ml) than did sFasL. These results indicate that sFasL derived
from various cellular backgrounds exhibits a comparable
and potent specific activity, suggesting that they might un-
dergo a similar processing.
MMP Inhibitors Induce Accumulation of Fast, on Cell Sur-
faces. To characterize human Fast, further, we generated
several mAbs. To avoid possible lethality of Fast,, Fas-defi-
cient MRL lpr/lpr mice (6) were immunized with hFasL/
L5178Y and the immune splenocytes were fused with
P3U1 myeloma. After screening the ability to neutralize
the Fast, activity in the hFasL/L5178Y supernatant, we es-
tablished three mAbs, termed NOK-1 (IgG1,ic), NOK-2
(IgG2a,ic), and NOK-3 (IgM,ic) . These mAbs neutralized
human Fast, activity 20-50-fold more efficiently than solu-
ble Fas-Ig fusion protein (Fig. 2). As represented in Fig. 3
A, NOK-1, as well as NOK-2 and NOK-3 (not shown),
reacted with hFasL/L5178Y but not with L5178Y, as esti-
mated by surface immunofluorescence and flow cytometry.
Recently, it has been demonstrated that the release of
TNF-a, which is homologous with Fast,, from activated T
cells and monocytes is mediated by metalloproteinase(s)
(15-17, 24) and that treatment with MMP inhibitors led to
surface accumulation of TNF-ct on these cells (17, 24). In
Figure 2.
￿
Neutralization of sFasL by anti-human Fast, mAbs and Fas-
Ig. Cytotoxic activity of sFasL in the supernatant of hFasL/L5178Y was
tested against hFas/WR19L (O,A,l],",A) or WR19L (") cells in the
absence (",") or presence ofserially diluted NOK-1 (O), NOK-2 (A),
NOK-3 (EI), or Fas-Ig (") by the Alamar blue method. Data represent
mean ± SD oftriplicate samples.B
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Figure 3 .
￿
Accumulation of Fas ligand on cell surface by BB94 treatment. (A) L5178Y and hFasL/L5178Y cells that had been cultured in the presence
(solid lines) or absence (broken lines) of 10 1L,M BB94 for 2 d were stained with biotinylated NOK-1 plus PE-avidin. Dotted lines indicate background
staining with PE-avidin alone. (B) Human CD4+ T cell clone 4HM1 that had been unstimulated or stimulated with P+1 for 2-6 h in the presence or ab-
sence of 10 l ..M BB94 was stained with biotinylated NOK-1 plus PE-avidin (solid lines) . Dotted lines indicate background staining with PE-avidin alone.
this context, we tested various protease inhibitors for their
ability to accumulate FasL on the surface of hFasL/L5178Y .
As represented with BB94 in Fig. 3 A, the treatments with
hydroxamic acid-based MMP inhibitors (BB94, KB8301,
andKB8112), which are similar to those used for inhibiting
the TNF-ot processing (15-17), greatly enhanced the stain-
ing with NOK-1. In contrast, a nonhydroxamic acid con-
trol compound (KB8845) or various inhibitors of other
proteases, including angiotensin-converting enzyme (capto-
pril, 100 LM), enkephalinase (phosphoramidon, 100 la,M),
serine proteases (aprotinin, 10 [LM), serine/cysteine proteases
1780
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(leupeptin, 100 LLM), cysteine proteases (E64, 100 iLM), as-
partyl proteases (pepstatin, 100 NLM), and aminopeptidases
(Bestatin, 100 p,M), were not effective (data not shown) . The
2-d BB94 treatment did not affect the steady-state level of
FasL mRNA in hFasL/L5178Y as estimated by Northern
hybridization (not shown), ruling out the possibility of en-
hanced transcription.
It has been demonstrated that the expression of FasL
mRNA and protein is induced in human T cells by stimu-
lation with PMA plus ionomycin (P+I) . We also observed
that a human CD4+ T cell clone, 4HM1, expressed FasL inA
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V
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Figure 4.
￿
Blocking of FasL release by MMP inhibitors. (A) hFasL/
L5178Y cells were cultured in the presence of the indicated doses of
KB8845 (O), KB8301 ("), BB94 ("), or KB8112 (") for 24 h. sFasL in
the supernatants was measured by ELISA. Data are indicated as a percent-
age of control ofsFasL in the absence ofinhibitors. (B) Human CD4+ T
cell clone 4HM1 was stimulated by immobilized OKT-3 in the presence
or absence of the indicated doses of BB94 (O,A,1]), or KB8112
After 24 h, IFN-y (O,"), sFasL (0,"), and TNF-a (i],") in
the supernatants were measured by ELISA. Data are represented as a per-
centage ofcontrol ofeach cytokine in the absence of inhibitors.
response to these stimulations, as estimated by Northern
hybridization and specific cytotoxicity against hFas/
WR19L (data not shown) . Consistently, NOK-1 did not
react with unstimulated 4HM1 but did react with P+I-
stimulated 4HM1 (Fig. 3 B). In the presence of BB94, the
level of surface FasL was progressively increased. KB8301
and KB8112 but neither KB8845 nor other protease inhib-
itors gave a similar result (data not shown) . Induction of
FasL mP NA was not affected by BB94, as estimated by
Northern hybridization (not shown) . These results sug-
gested that the MMP inhibitors induced the surface accu-
mulation of FasL on the transfectants and activated T cells
by inhibiting the processing by some MMP.
MMP Inhibitors Block sFasL Release.
￿
By utilizing NOK-1
and NOK-3, we established a sandwich ELISA system for
sFasL (see Materials and Methods), which enabled us to es-
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timate sFasL release quantitatively. We then examined the
effect of MMP inhibitors on sFasL release. The hydroxamic
acid-based MMP inhibitors (BB94, KB8301, and KB8112)
but not the non-hydroxamic acid control (KB8845) inhib-
ited the sFasL release from hFasL/L5178Y in a dose-depen-
dent manner (Fig. 4 A) . The other protease inhibitors
tested were not effective (not shown). In Fig. 4 B, we also
tested the effect of BB94 and KB8112 on the release of
sFasL, TNF-a, and IFN-y from OKT-3-stimulated
4HM1 . These MMP inhibitors inhibited the release of
sFasL and TNF-et comparably but not the release of IFN-y.
This result not only rules out an inhibitory effect of these
MMP inhibitors on T cell activation but also suggests a
close correlation between the TNF processing enzyme and
the FasL processing enzyme.
Biochemical Characterization of FasL Processing.
￿
The pro-
cessing of FasL was biochemically characterized by immu-
noprecipitation and SDS-PAGE analysis. To identify the
mFasL, hFasL/L5178Y cells were metabolically labeled
with [3'S]Cys/Met in the presence ofBB94, which leads to
accumulation ofmFasL. As represented in Fig. 5 A, NOK-1
specifically precipitated the 40-kD band (p40) under reduc-
ing and nonreducing conditions from the BB94-treated
hFasL/L5178Y but not from L5178Y (not shown). This
result appears to represent the mFasL as described in COS
cell transfectant (18). In some cases, an additional 80-kD
band (Fig. 5 A) and a faint 120-kD band were also detected
under nonreducing conditions, which might represent a
dimer and trimer, respectively, as described for sFasL (18).
On the other hand, sFasL was immunoprecipitated by
NOK-1 from the culture supernatant of 35S-Cys/Met-
labeled hFasL/L5178Y as a 27-kD band (p27) under non-
reducing and reducing conditions (Fig. 5 A) . Although oli-
gomers o£ sFasL were barely detected in our SDS-PAGE
analysis, FasL activity in the hFasL/L5178Y supernatant
was eluted around Mr of-80 kD in gel filtration (data not
shown), suggesting that sFasL is present as a trimer, as dem-
onstrated in the supernatant of COS cell transfectant (18).
NOK-1 immunoprecipitates from the surface biotinyl-
ated hFasL/L5178Y lysate typically exhibited two bands of
40 and 27 kD, which apparently represent mFasL and sFasL,
respectively (Fig. 4 B). The 27-kD band (p27) was also de-
tected occasionally in the lysate of [3IS]Cys/Met-labeled
hFasL/L5178Y cells (not shown). This suggests that some
sFasL is anchored on the cell surface as a part of partially
processed mFasL trimer like lymphotoxin-et anchored by
lymphotoxin-(3 (25). As represented in Fig. 5 B, an addi-
tional 60-kD band, whose identity is unknown, was also
detected occasionally.
We also examined the kinetics of the processing in acti-
vated T cells by pulse-chase analysis. PMA/ionomycin-
activated 4HM1 cells were pulse-labeled with [35S]Cys/
Met for 1 h and then chased in the culture medium with or
without BB94 (Fig. 5 C) . In the absence of BB94, mFasL
(p40) in the cell lysate was rapidly lost and, concomitantly,
sFasL (p27) was accumulated in the supernatant. In the
presence of BB94, the loss of p40 in the lysate and the ac-
cumulation of p27 in the supernatant were greatly reduced,ofp40 in the lysate or p27 in the supernatant when p40 in the 131394-treated cell lysate at 1 h and p27
100%, respectively.
demonstrating that BB94 is acting at the cell surface to in-
hibit FasL processing . Comparison of the band intensities
revealed that 75% of p40 was processed to p27 and 57%
was released into the supernatant within the first 1 h, indi-
cating a high efficiency of FasL processing on the activated
T cell surface .
This study indicated that human FasL is released from
the T cell surface via processing by some MMP, as was the
case with TNF-a . A closely correlated sensitivity to various
protease inhibitors raises a possibility that these two type II
integral membrane proteins may be processed by the same
metalloproteinase . In our preliminary study, activated T
cells express a limited repertoire ofknown MMPs, as re-
ported by others (26) . Identification of a candidate enzyme
Receivedfor publication 5July 1995 and in revisedform 7 August 1995 .
1782
￿
FasL Processing by Metalloproteinase
Figure 5 . Biochemical character-
ization of human FasL processing .
(A) FasL was immunoprecipitated
with NOK-1 or cIg from the cell ly-
sate (Cell) of 131394-treated hFasL/
L5178Y or the supernatant (Sup) of
hFasL/L5178Y after 3 S-Cys/Met
labeling. Immunoprecipitates were
resolved by SDS-PAGE (12% gel)
under nonreducing (NR) or reduc-
ing (R) conditions and autoradiogra-
phy. (B) FasL was immunoprecipi-
tated with NOK-1 or cIg from the
cell lysate of 131394-treated hFasL/
L5178Y or L5178Y cells after sur-
face biotinylation . Immunoprecipi-
tates were resolved by SDS-PAGE
(12% gel) under reducing condition
and transferred to nitrocellulose
membrane . Biotinylated FasL was
detected byABC and ECL . (C) Hu-
man CD4+ T cell clone 4HM 1 was
pulse labeled for 1 h with [3'S]Cys/
Met in the presence of PMA plus
ionomycin. The cells were chased in
fresh medium in the presence or ab-
sence of 10 j,M BB94 for 1-6 h .
FasL was immunoprecipitated with
NOK-1 from the cell lysates and su-
pernatants, and resolved by SDS-
PAGE (12% gel) under reducing
condition and autoradiography . The
positions of mFasL (p40) and sFasL
(p27) are indicated at the left and
right, respectively . Values under
each lane indicate relative intensity
in the untreated supernatant at 6 h are defined as
is now in progress . Recent studies demonstrated that ad-
ministration of an MMP inhibitor that blocked the TNF
processing protected mice from lethal endotoxin shock,
which is mainly mediated by macrophage-derived TNF
(15) . We also observed that KB8301 andBB94 have a sim-
ilar effect (unpublished data) . On the other hand, activated
T cell-derived FasL has been implicated in the pathogene-
sis of virus hepatitis and GVHD (12), in which TNF has
been also implicated (27) . In our preliminary study, some
patients suffering from fulminant hepatitis or GVHD ex-
hibited a high serum sFasL level, as estimated by the ELISA
(unpublished data) . Therefore, the MMP inhibitors that
block both sFasL and TNF release would be clinically use-
ful for the treatment of these diseases .
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